Thanks for your further comments, particularly regarding potential CVRs. I know that value is tenuous. Along with other shareholders, we are sitting with 10k long-held CVRs from a merger that resulted in ANIP appearing in our holdings. Those CVRS expire this year unless the results of a completed clinical trial are good enough to warrant marketing a commercial product—testosterone for females in need thereof.